Posted inCardiology Specialties
Evaluating Erythrocytosis Incidence and Thromboembolic Risk in HFrEF Patients Treated with SGLT2 Inhibitors
This article explores the incidence of erythrocytosis and thromboembolic risk in heart failure patients treated with SGLT2 inhibitors, revealing a higher incidence of erythrocytosis but no associated increase in thromboembolic events over one year.